CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD Chengdu Kanghong Pharmaceutical Group Co., Ltd Share Price
Equities
002773
CNE1000020C4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.39 CNY | -0.75% |
|
-1.41% | +21.42% |
| Sales 2022 | 3.39B 467M 39.02B | Sales 2023 | 3.96B 545M 45.56B | Capitalization | 16.95B 2.34B 195B |
|---|---|---|---|---|---|
| Net income 2022 | 897M 124M 10.33B | Net income 2023 | 1.04B 144M 12.03B | EV / Sales 2022 | 3.17 x |
| Net cash position 2022 | 3.68B 507M 42.37B | Net cash position 2023 | 4.7B 648M 54.11B | EV / Sales 2023 | 3.1 x |
| P/E ratio 2022 |
16
x | P/E ratio 2023 |
16.2
x | Employees | 4,289 |
| Yield 2022 |
0.96% | Yield 2023 |
2.06% | Free-Float | 28.85% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.75% | ||
| 1 week | -1.41% | ||
| Current month | +0.18% | ||
| 1 month | -5.57% | ||
| 3 months | +27.43% | ||
| 6 months | +17.72% | ||
| Current year | +21.42% |
1 week
22.17
22.99
1 month
21.9124.50
Current year
13.1524.50
1 year
13.1524.50
3 years
11.9524.50
5 years
11.9552.60
10 years
8.3854.15
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Jun Zhong
DFI | Director of Finance/CFO | 57 | - |
Xiao Ke
PSD | President | 41 | 01/12/01 |
Jin Qun Yin
BRD | Director/Board Member | 52 | 21/13/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Rong Zhong
BRD | Director/Board Member | 67 | 01/12/01 |
Zun Hong Ke
CHM | Chairman | 70 | 01/98/01 |
Xiao Ke
PSD | President | 41 | 01/12/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 22.39 | -0.75% | 6,868,745 |
| 13/24/13 | 22.56 | -0.49% | 6,156,350 |
| 12/24/12 | 22.67 | -1.13% | 7,028,141 |
| 11/24/11 | 22.93 | +0.97% | 8,810,140 |
| 07/24/07 | 22.71 | -3.24% | 19,097,540 |
End-of-day quote Shenzhen S.E., June 14, 2024
More quotes
Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Companyâs main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.42% | 2.84B | |
| +50.70% | 791B | |
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B |
- Stock Market
- Equities
- 002773 Stock
